Zhang Luankun

Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China.

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers40 papers

Sort

By YearBy Citation

Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma.

Shen Zhao,Wenfeng Fang, Hui Pan,Yunpeng Yang,Ying Liang,Lin Yang, Xiaorong Dong,Jianhua Zhan,Kai Wang,Li Zhang

Journal of thoracic oncology : official publication of the International Association for the Study o..., (2020)

WOSBibtex

319OCombined model of frameshift mutations and TMB in predicting response to immunotherapy in NSCLC

H Zhou,J Liu,Y Zhang, W Fang,L Zhang

(2019)

Bibtex

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

L. Paz-Ares,T.E. Ciuleanu,X. Yu,P. Salman, A. Pluzanski, A. Nagrial,L. Havel,R. Kowalyszyn,C. Audigier-Valette,Y.-L. Wu,H. Borghaei,M.D. Hellmann

Annals of Oncology, (2019)

Bibtex

P2.04-13 Interleukin-18 and Lung Cancer: A Mendelian Randomization Study

J. Liu,H. Zhou,Y. Zhang,W. Fang,Y. Yang,S. Hong,G. Chen,S. Zhao,Z. Zhang,J. Shen, W. Xian,Y. Huang

Journal of Thoracic Oncology, no. 10 (2019)

Bibtex

48PEducation and lung cancer: A Mendelian randomisation study

H Zhou,Y Zhang,J Liu,Y Yang,W Fang,S Hong,G Chen,S Zhao,Z Zhang,J Shen, W Xian,Y Huang

Annals of Oncology, (2019)

WOSBibtex

49PA Mendelian randomization study of the effects of Crohn’s disease on lung cancer

J Liu,H Zhou,Y Zhang,W Fang,Y Yang,S Hong,G Chen,S Zhao,J Shen, W Xian,Y Huang,H Zhao

Annals of Oncology, (2019)

WOSBibtex

60PNomogram for patients with stage I small cell lung cancer: A competing risk analysis

J Liu,H Zhou,Y Zhang,W Fang,Y Yang,S Hong,G Chen,S Zhao,X Chen,Z Zhang, W Xian,J Shen

Annals of Oncology, (2019)

WOSBibtex

P1.11-09 Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database

H. Zhou,J. Shen,Y. Zhang,Y. Huang,W. Fang,Y. Yang,S. Hong,G. Chen,S. Zhao,X. Chen,Z. Zhang,J. Liu

Journal of Thoracic Oncology, no. 10 (2019)

Bibtex

P109 Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients with Sensitive Relapsed SCLC

L. Zhang,X. Liu,Y. Cheng

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

P016 The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib

G. Chen, Y. Zhang, H. Zhou, S. Zhao,J. Liu,S. Hong,L. Zhang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

P102 The Correlations of Tumor Mutational Burden Among Single-region Tissue, Multi-region Tissues And Blood in NSCLC

Y. Zhang,W. Fang,Y. Yang, L. Chang,L. Zhang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

1477PEvaluation of progression-free survival (PFS) and one-year (1y) survival as surrogate endpoints (SE) in previously treated advanced non-small cell lung cancer (adNSCLC) in the era of immuno-oncology (IO)

Shen Zhao, Zhonghan Zhang,Tianshou Zhou,Y. Zhang,Longjuan Zhang

Annals of Oncology, (2018)

WOSBibtex

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer

Hongyun Zhao, Zhou Zhang, S. Li,Wentao Fang,Yuxiang Ma,Y. Zhang,Yang Y, F. Luo,Yan Huang,L. Zhang

Journal of Thoracic Oncology, no. 10 (2018)

Bibtex

P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032

Yuxiang Ma,Wenfeng Fang, S. Xie, Jieying Ge, H. Zhou,Li Zhang

Journal of Thoracic Oncology, no. 10 (2018)

Bibtex

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afatinib

S. Zhao,Wentao Fang,Yang Y,L. Zhang

Journal of Thoracic Oncology, no. 10 (2018)

Bibtex

MA02.05 A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC

Rajnish Nagarkar,Pere Gascón,Martin Smakal,Kostas Syrigos,Carlos H. Barrios, J. Cárdenas Sánchez,Li Zhang, D. Tomita, J. Park, C. De Oliveira Brandao

Journal of Thoracic Oncology, no. 10 (2018)

Cited by1Bibtex

OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses

Xiao Hu,Y. Bao, Y. Xu, H. Zhu,Jun O. Liu,L. Zhang, X. Yu,Y. Fan,Y. Zhang, W. Sun,W. Mao,Ming Chen

Journal of Thoracic Oncology, no. 10 (2018)

Bibtex

P026 Impact of Prior Cancer History on the Overall Survival of Younger Patients with Lung Cancer

H. Zhou, Y. Zhang,J. Liu,G. Chen, Z. Zhang,L. Zhang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

LBA10Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC

C Zhou,Y Lu,S-W Kim, T Reungwetwattana,J Zhou,Y Zhang,J He,J-J Yang,Y Cheng,S H Lee, L Bu, T Xu

Annals of Oncology, (2018)

WOSBibtex

383PWhether pericarcinomatous tissue of non-small cell lung cancer can serve as genetic background filter in next-generation sequencing analysis

Y Zhang,L Zhang, L Chang,Y Yang,W Fang,Y Guan,X Xia,X Yi

Annals of Oncology, (2018)

WOSBibtex

428PEfficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin

A Dechaphunkul,S Lu, S Olivari,L Zhang

Annals of Oncology, (2018)

WOSBibtex

P101 Intratumor Heterogeneity Comparison Among Different Subtypes of NSCLC Through Multi-region Tissue And ctDNA Sequencing

Y. Zhang,Y. Yang,W. Fang, L. Chang,L. Zhang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

OA10 CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)

Y. Wu,J. Chang,L. Zhang, H. Tu, L. Wu, J. Feng,S. Lu, C. Zhou, J. Wang,T. Mok,F. Taylor, B. Mossman

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

P038 Docosapentaenoic Acid and Lung Cancer Risk: A Mendelian Randomisation Study

J. Liu, H. Zhou, Y. Zhang,Y. Huang,W. Fang,Y. Yang,S. Hong,G. Chen, S. Zhao, X. Chen, Z. Zhang, J. Shen

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

W. Fang, S. Zhao, Y. Liang,Y. Yang, L. Yang, X. Dong,L. Zhang, Y. Tang, S. Wang,X. Ma, M. Wang,W. Wang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

P025 Which Is the Optimal Immunotherapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer in Combination with Chemotherapy?

H. Zhoum, Y. Zhang,G. Chen, S. Zhao,J. Liu,S. Hong,L. Zhang

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

136PLong-term safety and efficacy of darbepoetin alfa in subjects with stage IV NSCLC receiving multi-cycle chemotherapy

Pere Gascón, Rajnish Nagarkar,Martin Smakal,Kostas Syrigos,Carlos H. Barrios, J. Cárdenas Sánchez,Li Zhang,David H. Henry, D. Tomita, C. De Oliveira Brandao

Annals of Oncology, (2017)

Bibtex

142TiPA prospective multi-center study to investigate the EGFR-TKI resistance profile, treatment algorithm and clinical outcome in Chinese patients with advanced EGFRm+ NSCLC who have received prior first generation EGFR TKI (PRECENT study, CCTC-1601, NCT02988141)

Wenhua Liang, L. Wu,L. Wang,Yan Huang,R. Xu,L. Zhang,Jiaxi He

Annals of Oncology, (2017)

Bibtex

100PAfatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment

J.C-H. Yang,L. Paz-Ares, E-H. Tan,K. O'Byrne,L. Zhang,M. Boyer,T. Mok,V. Hirsh, J. Fan,K. Park

Annals of Oncology, (2017)

Bibtex

440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)

K. Park,E.H. Tan,L. Zhang,Vera Hirsh,Kenneth J. O'Byrne,Michael Boyer, J.C-H. Yang,T. Mok, K H Lee,Shun Lu,Yuankai Shi, S. Kim

Annals of Oncology, (2016)

Bibtex

Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial

Martin Schuler, E.H. Tan,Kenneth J. O'Byrne,L. Zhang,Michael Boyer,T. Mok,Vera Hirsh, J.C-H. Yang, K H Lee,Shun Lu,Yuankai Shi,S. Kim

Annals of Oncology, (2016)

Bibtex

397PD KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma

Shaodong Hong, N. Chen,Wenfeng Fang, J. Zhan,L. Zhang

Annals of Oncology, (2016)

Bibtex

Pooled analysis of treatment-related hypothyroidism with anti-PD-1/PD-L1 therapies in cancer patients

Shaodong Hong,Wenfeng Fang,L. Zhang

Annals of Oncology, (2016)

Bibtex

Receptor-interacting protein 140 overexpression impairs cardiac mitochondrial function and accelerates the transition to heart failure in chronically infarcted rats.

YanFang Chen,ShaoRui Chen,ZhongBao Yue,YiQiang Zhang,ChangHua Zhou,WeiWei Cao,Xi Chen,LuanKun Zhang,PeiQing Liu

Translational research : the journal of laboratory and clinical medicine, (2016)

WOSBibtex

Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs

L. Zhang,Jin Sheng,Yelin Huang,Yunpeng Yang,Hongyun Zhao,Wenfeng Fang,Yuanyuan Zhao, Y. Zhang

Annals of Oncology, (2016)

Bibtex

SLC41A1 knockdown inhibits angiotensin II-induced cardiac fibrosis by preventing Mg(2+) efflux and Ca(2+) signaling in cardiac fibroblasts.

Na Yu,Jianmin Jiang,Yang Yu,Hong Li,Xiaoyang Huang,Yunzi Ma,Luankun Zhang,Jian Zou,Boyu Zhang,Shaorui Chen,Peiqing Liu

Archives of biochemistry and biophysics, (2014): 74-82

Cited by3WOSBibtex

1262PMULTI-TARGETED ANTIANGIOGENIC TYROSINE KINASE INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER: AN UPDATED META-ANALYSIS OF 20 RANDOMIZED CONTROLLED TRIALS AND SUBGROUP ANALYSES

Weiching Liang,Xudong Wu,Lei Zhang

Annals of oncology : official journal of the European Society for Medical Oncology, no. suppl_4 (2014)

WOSBibtex

1301PTHE EFFICACY OF FIRST-LINE CHEMOTHERAPY IS ASSOCIATED WITH KRAS MUTATION STATUS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A META-ANALYSIS

Yongdong Zhang,Liping Zhang,Wannian Liang, Manna Wang, Seongryong Kang,Wei Fang, Xindong Wu,Sughun Hong,J Sheng

Annals of oncology : official journal of the European Society for Medical Oncology, no. suppl_4 (2014)

WOSBibtex

A Phase II Study of Sorafenib Monotherapy in the Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer After Failure of Egfr-Tki (CTONG0805)

Q. Zhou,C. Zhou,G. Chen,Y. Cheng,C. Huang,L. Zhang,Y.-L. Wu

Annals of Oncology, (2012)

Bibtex

Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer: Phase III, Randomized, Double-Blind, Placebo-Controlled Mission Trial

L. Paz-Ares,V. Hirsh,L. Zhang,F. De Marinis,J.C-H. Yang,H. Wakelee,T. Seto,T. Schmelter,T.J. Ong,T.S.K. Mok,E.F. Smit

Annals of Oncology, (2012)

Bibtex

View All

Base Info Papers Patents Projects